TURINOVER 100 tabs x 10mg CDMT

Comprehensive Clinical, Pharmacological, and Structural Profile of Turinover (Chlorodehydromethyltestosterone 10mg)

Profile of Turinover and Chemical Structure

Turinover is an oral pharmaceutical presentation formulated with 4-Chlorodehydromethyltestosterone (commonly abbreviated as CDMT) at a strength of 10mg per tablet, packaged in a quantity of 100 tablets. Identified chemically as 4-chloro-17β-hydroxy-17α-methylandrosta-1,4-dien-3-one, CDMT is a synthetic derivative of testosterone that combines structural attributes from two distinct anabolic compounds: methandrostenolone (Dianabol) and clostebol (4-chlorotestosterone).

The molecular framework of CDMT features double bonds at positions C1 and C2 alongside C4 and C5 in the A-ring, combined with a crucial chlorine substitution at the C4 position and a methyl group at the C17-alpha position. This specific combination yields unique biochemical characteristics:

• Prevention of Enzymatic Aromatization: The presence of the chlorine atom at position C4 creates steric hindrance that prevents binding with the aromatase enzyme, completely eliminating estrogenic conversion.
• Oral Bioavailability: The C17-alpha alkylation prevents metabolic inactivation by first-pass liver degradation, ensuring strong systemic activity following oral consumption.
• Moderate Androgenic Impact: The molecular alterations alter binding affinity to tissue androgen receptors, resulting in high tissue-building potency with decreased androgenic reactivity relative to basic testosterone molecules.

Through these structural design choices, Turinover exhibits a favorable anabolic-to-androgenic ratio, making the compound an important subject of analysis in physical conservation, athletic pharmacology, and nitrogen retention research.

Intracellular Mechanisms and Bio-Molecular Actions

Turinover exerts its effects by crossing cell membranes and binding directly to androgen receptors within target tissues, including skeletal muscle fibers, bone cells, and neural networks. Upon binding, the androgen-receptor complex undergoes conformational shifts and translocates into the cellular nucleus. Inside the nucleus, it interacts with androgen response elements on chromatin to upregulate protein synthesis, accelerate cellular repair mechanisms, and enhance nitrogen retention.

Beyond its primary androgen receptor activity, CDMT demonstrates several notable metabolic characteristics:

• Reduction of Sex Hormone-Binding Globulin: CDMT displays a significant affinity for Sex Hormone-Binding Globulin (SHBG). By occupying binding sites on circulating SHBG molecules, it reduces overall SHBG activity, increasing the proportion of active, unbound free testosterone and other circulating hormones in blood plasma.
• Absence of Estrogenic Conversion: Because CDMT is structurally incapable of converting into estradiol via aromatization, therapy with Turinover carries zero intrinsic risk of direct estrogen-mediated side effects, such as fluid accumulation in subcutaneous tissues